Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-069367
Filing Date
2025-05-12
Accepted
2025-05-12 16:45:23
Documents
72
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q avir-20250331.htm   iXBRL 10-Q 2209073
2 EX-10.1 avir-ex10_1.htm EX-10.1 645843
3 EX-31.1 avir-ex31_1.htm EX-31.1 15618
4 EX-31.2 avir-ex31_2.htm EX-31.2 15848
5 EX-32.1 avir-ex32_1.htm EX-32.1 10989
6 EX-32.2 avir-ex32_2.htm EX-32.2 10303
7 GRAPHIC img144878150_0.jpg GRAPHIC 2534
8 GRAPHIC img144878150_1.jpg GRAPHIC 2534
  Complete submission text file 0000950170-25-069367.txt   8774379

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT avir-20250331.xsd EX-101.SCH 992485
75 EXTRACTED XBRL INSTANCE DOCUMENT avir-20250331_htm.xml XML 1370302
Mailing Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110
Business Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110 857-204-8109
Atea Pharmaceuticals, Inc. (Filer) CIK: 0001593899 (see all company filings)

EIN.: 460574869 | State of Incorp.: MA | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39661 | Film No.: 25935598
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)